Rinvoq vs. Hadlima

Rinvoq (upadacitinib) and Hadlima (adalimumab-bwwd) are used to treat adults with moderately to severely active rheumatoid arthritis.

Hadlima is also used to treat juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps).

Hadlima is biosimilar to Humira (adalimumab).

Rinvoq and Hadlima belong to different drug classes. Rinvoq is a Janus kinase (JAK) inhibitor and Hadlima is a tumor necrosis factor (TNF) blocker.

Side effects of Rinvoq and Hadlima that are similar include upper respiratory tract infections.

Side effects of Rinvoq that are different from Hadlima include nausea, cough, and fever.

Side effects of Hadlima that are different from Rinvoq include injection site reactions (redness, itching, bleeding, pain, and swelling), headache, and rash.

Both Rinvoq and Hadlima may interact with live vaccines.

Rinvoq may also interact with strong CYP3A4 inhibitors (e.g., ketoconazole) and strong CYP3A4 inducers (e.g., rifampin).

Hadlima may also interact with abatacept, anakinra, warfarin, cyclosporine, and theophylline.

Common side effects of Rinvoq include:

• upper respiratory tract infections,
• nausea,
• cough, and
• fever

Side effects of Hadlima nclude<:/p>

• infections (e.g. upper respiratory tract, sinusitis),
• injection site reactions (redness, itching, bleeding, pain, and swelling),
• headache, and
• rash

Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

Hadlima (adalimumab-bwwd) is a tumor necrosis factor (TNF) blocker indicated for treatment of rheumatoid Arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC), and plaque psoriasis (Ps). Hadlima is biosimilar to Rituxan (adalimumab).

Rinvoq may interact with strong CYP3A4 inhibitors (e.g., ketoconazole), strong CYP3A4 inducers (e.g., rifampin), and live vaccines. Tell your doctor all medications and supplements you use. Rinvoq is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Rinvoq and for 4 weeks following completion of therapy. It is unknown if Rinvoq passes into breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with Rinvoq, and for 6 days after the last dose.

Hadlima may interact with abatacept, anakinra, warfarin, cyclosporine, theophylline, and live vaccines.

The recommended dose of Rinvoq is 15 mg once daily. Rinvoq may be used as monotherapy or in combination with methotrexate or other nonbiologic DMARDs.

The dose of Rituxan to treat adult rheumatoid arthritis and psoriatic arthritis is 50 mg once weekly with or without methotrexate (MTX). The dose of Rituxan to treat ankylosing spondylitis is 50 mg once weekly. The dose of Rituxan to treat adult plaque psoriasis is 50 mg twice weekly for 3 months, followed by 50 mg once weekly. The dose of Rituxan to treat pediatric plaque psoriasis or plaque psoriasis (patients who weigh 63 kg or more) is 50 mg once weekly.